Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

How do breast cancers become hormone resistant?

K B Horwitz1

  • 1University of Colorado Health Sciences Center, Denver 80262.

The Journal of Steroid Biochemistry and Molecular Biology
|June 1, 1994
PubMed
Summary

Tumor cell heterogeneity, driven by estrogen receptor (ER) mutations, causes varied responses to tamoxifen. This suggests caution in using tamoxifen for breast cancer prevention due to potential tumor cell stimulation.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Insulin receptor substrates mediate distinct biological responses to insulin-like growth factor receptor activation in breast cancer cells.

British journal of cancer·2006
Same author

Progesterone pre-treatment potentiates EGF pathway signaling in the breast cancer cell line ZR-75.

Breast cancer research and treatment·2005
Same author

Desferri-exochelin induces death by apoptosis in human breast cancer cells but does not kill normal breast cells.

Breast cancer research and treatment·2002
Same author

Mapping the unique activation function 3 in the progesterone B-receptor upstream segment. Two LXXLL motifs and a tryptophan residue are required for activity.

The Journal of biological chemistry·2001
Same author

Transcriptional hyperactivity of human progesterone receptors is coupled to their ligand-dependent down-regulation by mitogen-activated protein kinase-dependent phosphorylation of serine 294.

Molecular and cellular biology·2001
Same author

The N-terminal region of human progesterone B-receptors: biophysical and biochemical comparison to A-receptors.

The Journal of biological chemistry·2001

Area of Science:

  • Oncology
  • Molecular Biology
  • Endocrinology

Background:

  • Estrogen receptor (ER) and progesterone receptor (PR) heterogeneity is observed in breast tumors.
  • Cellular heterogeneity in breast cancer impacts treatment response.

Purpose of the Study:

  • To investigate how molecular heterogeneity of ER and PR in breast cancer cells influences cellular heterogeneity and tamoxifen response.
  • To understand the implications of PR heterogeneity in predicting patient response to antiestrogen therapy.

Main Methods:

  • Analysis of progesterone receptor (PR) distribution and DNA ploidy in breast cancer cell subpopulations.
  • Assessment of cellular remodeling under tamoxifen influence.

Main Results:

  • Molecular heterogeneity of ER, characterized by mutant forms, generates cellular heterogeneity in PR and DNA ploidy.
  • Tamoxifen treatment remodels mixed breast cancer cell subpopulations, leading to differential inhibition or stimulation.
  • PR heterogeneity in patient tumors may predict a mixed response to antiestrogen treatment.

Conclusions:

  • Cellular heterogeneity, driven by ER mutations, leads to varied responses to tamoxifen, necessitating caution in its use.
  • Understanding PR heterogeneity is crucial for predicting treatment outcomes and identifying potentially dangerous cell subpopulations.

Related Experiment Videos